Excellos

Executive Summary

Excellos is a San Diego-based cell therapy CDMO offering end-to-end services from donor cell sourcing and deep characterization to GMP manufacturing for adoptive cell therapies. Its proprietary Excellos 360 platform leverages comprehensive immune profiling to reduce donor variability and improve clinical outcomes. As a privately held Phase 1 company, Excellos focuses on serving the growing demand for outsourced cell therapy manufacturing, positioning itself as a key enabler for biotech developers without in-house capabilities. With its integrated platform and strategic location in a major biotech hub, Excellos is well-positioned to capture market share as cell therapies advance through clinical trials toward commercialization.

Upcoming Catalysts (preview)

• Q4 2026Next-gen GMP facility expansion70% success
• Q2 2026Partnership with major pharma for CDMO services60% success
• Q3 2026Validation of Excellos 360 platform in peer-reviewed publication80% success